Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iProfiler modular multi-basket matched-therapy trial in advanced solid tumors
NL-OMON59079Phase 2Recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Feb 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab in Nonhematologic neoplasms (3 cohorts), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Overall response rate, Complete response and 1 more. Started Feb 2019; status: recruiting.
02
Drugs
amivantamab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59079.